{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T12:59:25Z","timestamp":1791377965504,"version":"4.3.2"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T00:00:00Z","timestamp":1583280000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Programmed cell death 1 (PD-1) is one of the immune checkpoint molecules that negatively regulate the function of T cells. Although recent studies indicate that PD-1 is also expressed on other immune cells besides T cells, its role remains unclear. This study aims to evaluate PD-1 expression on macrophages and examine its effect on anti-tumor immunity in gastric cancer (GC) patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      The frequency of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophages obtained from GC tissue was determined by multicolor flow cytometry (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200915). Double immunohistochemistry staining of PD-1 and CD68 was also performed to evaluate the correlations among the frequency of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophages, clinicopathological characteristics, and prognosis in GC patients (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009102).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The frequency of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophages was significantly higher in GC tissue than in non-tumor gastric tissue. The phagocytotic activity of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophages was severely impaired compared with that of PD-1\n                      <jats:sup>\u2212<\/jats:sup>\n                      macrophages. The 5-year disease-specific survival rates in patients with PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophage\n                      <jats:sup>Low<\/jats:sup>\n                      (the frequency of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophages; &lt;\u20090.85%) and those with PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophage\n                      <jats:sup>High<\/jats:sup>\n                      (the frequency of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophages; \u2265 0.85%) were 85.9 and 65.8%, respectively (\n                      <jats:italic>P<\/jats:italic>\n                      \u00a0=\u20090.008). Finally, multivariate analysis showed the frequency of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophage to be an independent prognostic factor.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The function of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophage was severely impaired and increased frequency of PD-1\n                      <jats:sup>+<\/jats:sup>\n                      macrophage worsened the prognosis of GC patients. PD-1\u2013PD-L1 therapies may function through a direct effect on macrophages in GC.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-020-6629-6","type":"journal-article","created":{"date-parts":[[2020,3,4]],"date-time":"2020-03-04T09:03:08Z","timestamp":1583312588000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Increased PD-1-positive macrophages in the tissue of gastric cancer are closely associated with poor prognosis in gastric cancer patients"],"prefix":"10.1186","volume":"20","author":[{"given":"Yusuke","family":"Kono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7675-0754","authenticated-orcid":false,"given":"Hiroaki","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Miyauchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shota","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Shishido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kozo","family":"Miyatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Matsunaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Fukumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Nakayama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiye","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyotaka","family":"Hatsuzawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Fujiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,3,4]]},"reference":[{"issue":"11","key":"6629_CR1","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/S1470-2045(19)30626-6","volume":"20","author":"K Kato","year":"2019","unstructured":"Kato K, Cho BC, Takahashi M, Okada M, Lin CY, Chin K, et al. Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(11):1506\u201317.","journal-title":"Lancet Oncol"},{"issue":"25","key":"6629_CR2","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1056\/NEJMoa1613493","volume":"376","author":"DP Carbone","year":"2017","unstructured":"Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line Nivolumab in stage IV or recurrent non-small-cell lung Cancer. N Engl J Med. 2017;376(25):2415\u201326.","journal-title":"N Engl J Med"},{"issue":"11","key":"6629_CR3","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee JL, Fong L, et al. Pembrolizumab as second-line therapy for advanced Urothelial carcinoma. N Engl J Med. 2017;376(11):1015\u201326.","journal-title":"N Engl J Med"},{"issue":"15","key":"6629_CR4","doi-asserted-by":"publisher","first-page":"6303","DOI":"10.1073\/pnas.0809422106","volume":"106","author":"X Huang","year":"2009","unstructured":"Huang X, Venet F, Wang YL, Lepape A, Yuan Z, Chen Y, et al. PD-1 expression by macrophages plays a pathologic role in altering microbial clearance and the innate inflammatory response to sepsis. Proc Natl Acad Sci U S A. 2009;106(15):6303\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"9","key":"6629_CR5","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.4049\/jimmunol.1402550","volume":"194","author":"AP Bally","year":"2015","unstructured":"Bally AP, Lu P, Tang Y, Austin JW, Scharer CD, Ahmed R, et al. NF-kappaB regulates PD-1 expression in macrophages. J Immunol. 2015;194(9):4545\u201354.","journal-title":"J Immunol"},{"key":"6629_CR6","doi-asserted-by":"publisher","first-page":"e2115","DOI":"10.1038\/cddis.2016.33","volume":"7","author":"W Chen","year":"2016","unstructured":"Chen W, Wang J, Jia L, Liu J, Tian Y. Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan. Cell Death Dis. 2016;7:e2115.","journal-title":"Cell Death Dis"},{"key":"6629_CR7","doi-asserted-by":"publisher","first-page":"38362","DOI":"10.1038\/srep38362","volume":"6","author":"L Shen","year":"2016","unstructured":"Shen L, Gao Y, Liu Y, Zhang B, Liu Q, Wu J, et al. PD-1\/PD-L pathway inhibits M.tb-specific CD4(+) T-cell functions and phagocytosis of macrophages in active tuberculosis. Sci Rep. 2016;6:38362.","journal-title":"Sci Rep"},{"issue":"7655","key":"6629_CR8","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, McCracken MN, et al. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545(7655):495\u20139.","journal-title":"Nature"},{"issue":"6","key":"6629_CR9","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394\u2013424.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"6629_CR10","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1002\/jso.23281","volume":"107","author":"H Saito","year":"2013","unstructured":"Saito H, Kuroda H, Matsunaga T, Osaki T, Ikeguchi M. Increased PD-1 expression on CD4+ and CD8+ T cells is involved in immune evasion in gastric cancer. J Surg Oncol. 2013;107(5):517\u201322.","journal-title":"J Surg Oncol"},{"issue":"10111","key":"6629_CR11","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (London, England). 2017;390(10111):2461\u201371.","journal-title":"Lancet (London, England)"},{"issue":"2","key":"6629_CR12","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s10120-011-0041-5","volume":"14","author":"Japanese Gastric Cancer Association","year":"2011","unstructured":"Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101\u201312.","journal-title":"Gastric Cancer"},{"issue":"1","key":"6629_CR13","doi-asserted-by":"publisher","first-page":"13083","DOI":"10.1038\/s41598-019-49581-4","volume":"9","author":"Y Murakami","year":"2019","unstructured":"Murakami Y, Saito H, Shimizu S, Kono Y, Shishido Y, Miyatani K, et al. Increased regulatory B cells are involved in immune evasion in patients with gastric cancer. Sci Rep. 2019;9(1):13083.","journal-title":"Sci Rep"},{"issue":"4","key":"6629_CR14","first-page":"291","volume":"23","author":"AC Ruifrok","year":"2001","unstructured":"Ruifrok AC, Johnston DA. Quantification of histochemical staining by color deconvolution. Anal Quant Cytol Histol. 2001;23(4):291\u20139.","journal-title":"Anal Quant Cytol Histol"},{"issue":"5","key":"6629_CR15","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00428-016-1914-0","volume":"468","author":"K Miyatani","year":"2016","unstructured":"Miyatani K, Saito H, Murakami Y, Watanabe J, Kuroda H, Matsunaga T, et al. A high number of IgG4-positive cells in gastric cancer tissue is associated with tumor progression and poor prognosis. Virchows Arch. 2016;468(5):549\u201357.","journal-title":"Virchows Arch"},{"issue":"11","key":"6629_CR16","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11(11):3887\u201395.","journal-title":"EMBO J"},{"issue":"7","key":"6629_CR17","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192(7):1027\u201334.","journal-title":"J Exp Med"},{"issue":"7077","key":"6629_CR18","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nature04444","volume":"439","author":"DL Barber","year":"2006","unstructured":"Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH, et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature. 2006;439(7077):682\u20137.","journal-title":"Nature"},{"key":"6629_CR19","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"17","key":"6629_CR20","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1073\/pnas.1003345107","volume":"107","author":"J Matsuzaki","year":"2010","unstructured":"Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107(17):7875\u201380.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"6629_CR21","first-page":"765","volume":"62","author":"ME Nunn","year":"1979","unstructured":"Nunn ME, Herberman RB. Natural cytotoxicity of mouse, rat, and human lymphocytes against heterologous target cells. J Natl Cancer Inst. 1979;62(4):765\u201371.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"6629_CR22","first-page":"257","volume":"65","author":"BM Vose","year":"1980","unstructured":"Vose BM, Moore M. Natural cytotoxicity in humans: susceptibility of freshly isolatd tumor cells to lysis. J Natl Cancer Inst. 1980;65(2):257\u201363.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"6629_CR23","first-page":"1093","volume":"73","author":"A Uchida","year":"1984","unstructured":"Uchida A, Yanagawa E. Natural killer cell activity and autologous tumor killing activity in cancer patients: overlapping involvement of effector cells as determined in two-target conjugate cytotoxicity assay. J Natl Cancer Inst. 1984;73(5):1093\u2013100.","journal-title":"J Natl Cancer Inst"},{"issue":"44","key":"6629_CR24","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, et al. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36(44):6143\u201353.","journal-title":"Oncogene"},{"issue":"5","key":"6629_CR25","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1158\/2159-8290.CD-15-1408","volume":"6","author":"X Xiao","year":"2016","unstructured":"Xiao X, Lao XM, Chen MM, Liu RX, Wei Y, Ouyang FZ, et al. PD-1hi identifies a novel regulatory B-cell population in human Hepatoma that promotes disease progression. Cancer Discov. 2016;6(5):546\u201359.","journal-title":"Cancer Discov"},{"issue":"11","key":"6629_CR26","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S1471-4906(02)02302-5","volume":"23","author":"A Mantovani","year":"2002","unstructured":"Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol. 2002;23(11):549\u201355.","journal-title":"Trends Immunol"},{"issue":"1","key":"6629_CR27","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.immuni.2014.06.008","volume":"41","author":"PJ Murray","year":"2014","unstructured":"Murray PJ, Allen JE, Biswas SK, Fisher EA, Gilroy DW, Goerdt S, et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity. 2014;41(1):14\u201320.","journal-title":"Immunity"},{"key":"6629_CR28","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/1479-5876-9-216","volume":"9","author":"M Heusinkveld","year":"2011","unstructured":"Heusinkveld M, van der Burg SH. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med. 2011;9:216.","journal-title":"J Transl Med"},{"issue":"6","key":"6629_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.ejca.2006.01.003","volume":"42","author":"A Sica","year":"2006","unstructured":"Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer (Oxford, England : 1990). 2006;42(6):717\u201327.0.","journal-title":"Eur J Cancer (Oxford, England : 1990)"},{"issue":"1","key":"6629_CR30","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/nrc1256","volume":"4","author":"JW Pollard","year":"2004","unstructured":"Pollard JW. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer. 2004;4(1):71\u20138.","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"6629_CR31","first-page":"107","volume":"38","author":"H Saito","year":"2018","unstructured":"Saito H, Kono Y, Murakami Y, Shishido Y, Kuroda H, Matsunaga T, et al. Highly activated PD-1\/PD-L1 pathway in gastric Cancer with PD-L1 expression. Anticancer Res. 2018;38(1):107\u201312.","journal-title":"Anticancer Res"},{"issue":"3","key":"6629_CR32","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1007\/s10120-018-0880-4","volume":"22","author":"S Sasaki","year":"2019","unstructured":"Sasaki S, Nishikawa J, Sakai K, Iizasa H, Yoshiyama H, Yanagihara M, et al. EBV-associated gastric cancer evades T-cell immunity by PD-1\/PD-L1 interactions. Gastric Cancer. 2019;22(3):486\u201396.","journal-title":"Gastric Cancer"},{"issue":"3","key":"6629_CR33","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1007\/s10120-016-0631-3","volume":"20","author":"A Kawazoe","year":"2017","unstructured":"Kawazoe A, Kuwata T, Kuboki Y, Shitara K, Nagatsuma AK, Aizawa M, et al. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients. Gastric Cancer. 2017;20(3):407\u201315.","journal-title":"Gastric Cancer"},{"key":"6629_CR34","doi-asserted-by":"publisher","first-page":"3909","DOI":"10.2147\/CMAR.S203035","volume":"11","author":"B Shen","year":"2019","unstructured":"Shen B, Qian A, Lao W, Li W, Chen X, Zhang B, et al. Relationship between helicobacter pylori and expression of programmed death-1 and its ligand in gastric intraepithelial neoplasia and early-stage gastric cancer. Cancer Manag Res. 2019;11:3909\u201319.","journal-title":"Cancer Manag Res"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6629-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12885-020-6629-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-020-6629-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,3]],"date-time":"2021-03-03T19:12:01Z","timestamp":1614798721000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-020-6629-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,4]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["6629"],"URL":"https:\/\/doi.org\/10.1186\/s12885-020-6629-6","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.18131\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18131\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.18131\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,3,4]]},"assertion":[{"value":"17 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 February 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and later versions. Written informed consent to be included in the study was obtained from all patients.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"175"}}